Unwanted immunogenicity, its characteristics, and clinical significance is at present very difficult, if not impossible to predict based on simple models.
I am simply questioning the blanket statement that all phylomers, being up to 50mer, will have problems - this is not justified. Even some human antibody therapeutics can evoke a significant anti-body response.
Phylomer libraries are not drug libraries. Phylomers are screened for activity; to produce a drug requires further transformation (for stability, activity, anti-toxicity, etc.) - pharmacology properties.
I have a friend with a PhD from Harvard Medical School and UMASS where he worked as an oncologist and immunologist. I'll get his view on phylomer immunogenicity, phage display and yeast-two-hybrid screening technologies for peptides and report back to the thread.
- Forums
- ASX - By Stock
- Ann: Core patent granted in Australia
Unwanted immunogenicity, its characteristics, and clinical...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $629.9M |
Open | High | Low | Value | Volume |
13.5¢ | 13.5¢ | 12.5¢ | $919.8K | 7.025M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12715 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 276517 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8400 | 0.130 |
3 | 516000 | 0.125 |
7 | 97726 | 0.120 |
6 | 971565 | 0.115 |
4 | 231634 | 0.110 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 276517 | 3 |
0.140 | 1863642 | 7 |
0.145 | 750000 | 2 |
0.150 | 762617 | 6 |
0.165 | 28000 | 2 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online